Clik here to view.
Psychosocial Needs of Aging Patients with Hemophilia the Focus of Partners...
This activity aims to help HTC providers address the evolving psychosocial nees of an aging hemophilia population that grapples with the complications of aging.Read more about Psychosocial Needs of...
View ArticleClik here to view.
Alnylam Announces Successful Meeting with FDA on Fitusiran
Alnylam is developing the therapy to treat patients with hemophilia A and B, both with and without inhibitors.Read more about Alnylam Announces Successful Meeting with FDA on Fitusiran
View ArticleClik here to view.
THSNA Summit Coming in March 2018
Learn about the most current clinical and scientific issues related to hemostasis and thrombosis.Read more about THSNA Summit Coming in March 2018
View ArticleClik here to view.
Call to Action on Senate Tax Plan
Call your Senators now and share how the tax reform proposal will harm the bleeding disorders community.Read more about Call to Action on Senate Tax Plan
View ArticleClik here to view.
FDA Approves Once-Weekly Subcutaneous Therapy for Hemophilia A Patients with...
The U.S. Food and Drug Administration (FDA) has approved HEMLIBRA® (emicizumab) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children with hemophilia A...
View ArticleFDA Grants Orphan Drug Designation for Rofecoxib, Pain Medication for...
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to TRM-201 (rofecoxib), a class of COX-2 selective non-steroidal anti-inflammatory drug (NSAID) for the treatment of...
View ArticleFirst Patient Enrolled in ITI Trial Using Eloctate
Swedish Orphan Biovitrum (Sobi) recently announced the successful enrollment of the first hemophilia A patient in the company’s ReITIrate clinical trial. The phase 4 study, which is being sponsored by...
View ArticleClinician Monographs Available through NHF Resource Center
The National Hemophilia Foundation (NHF) would like to make healthcare providers aware of three monographs that are available through NHF’s resource center HANDI. Each booklet is devoted to a key...
View ArticlePartners Module Addresses Psychosocial Considerations in Children with...
The Partners in Bleeding Disorders Education Program recently launched “Psychosocial Considerations in Bleeding Disorder Care: Birth to Preadolescence.” This online learning activity is focused on the...
View ArticleClik here to view.
"Action to Hope" Study Open to Hemophilia Community
The study seeks to shed light on the barriers people with hemophilia who are obese or overweight have to losing weight.Read more about "Action to Hope" Study Open to Hemophilia Community
View ArticleClik here to view.
NHF Announces the 2017 NHF/Novo Nordisk Career Development Award Recipient
NHF is pleased to announce Christopher J. Ng, MD, Assistant Professor of Pediatrics, University of Colorado Denver, as the recipient of the 2017 NHF/Novo Nordisk Career Development Award (CDA).Read...
View ArticleClik here to view.
It's Not Too Late: Take Action on Tax Reform
Read more about It's Not Too Late: Take Action on Tax Reform
View ArticleClik here to view.
HEMLIBRA® Shows Prophylactic Efficacy in Hemophilia A Patients without...
Genentech recently reported results from the phase III HAVEN 3 study, which showed that the prophylactic use of HEMLIBRA® led to significantly reduced bleeds in adult and adolescent patients with...
View ArticleClik here to view.
NHF Healthcare Update: Congressional To-Do List
Congress has a lengthy to-do list before the end of the year. NHF is closely monitoring numerous issues affecting the bleeding disorders community including:Tax ReformRead more about NHF Healthcare...
View ArticleSpark Reports Positive Clinical Trial Data on Hemophilia A and B Gene...
Spark Therapeutics provided clinical trial updates on the company’s investigational gene therapies for hemophilia A and B, known respectively as SPK-8011 and SPK-9001. The updates were presented at the...
View ArticleShire and Rani Agree to Collaborate on Development of Orally-Administered...
In a recent press release Shire announced that they have entered into a collaboration agreement with Rani Therapeutics. This agreement allows Shire to conduct research on the use of Rani Pill™...
View ArticleClik here to view.
Alnylam Announces FDA Lift of Hold on Fitusiran Trials
The FDA has lifted a hold on clinical studies involving the investigational therapy fitusiran.Read more about Alnylam Announces FDA Lift of Hold on Fitusiran Trials
View ArticleClik here to view.
Survey for African Americans and Latinos with Hemophilia and VWD Type III
People who are African-American or Latino and have hemophilia A or B, or VWD type 3 are at an increased risk of developing an inhibitor.Read more about Survey for African Americans and Latinos with...
View ArticleClik here to view.
BioMarin Reports Positive Gene Therapy Trial Data at ASH
BioMarin provided a series of updates on their investigational hemophilia A gene therapy candidate valoctocogene roxaparvovec.Read more about BioMarin Reports Positive Gene Therapy Trial Data at ASH
View ArticleClik here to view.
NHF Statement on Shire Injunction Filing on Roche/Genentech
NHF is aware that recently Shire sought an injunction against Roche/Genentech.Read more about NHF Statement on Shire Injunction Filing on Roche/Genentech
View Article